Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the safety or effectiveness of these vaccines.1

In studies of children (AD-1652) and adolescents (AD-1526), patients were excluded if they were treated with a live (attenuated) vaccine within 4 weeks before the baseline visit.2

  • Patients for whom administration of a live (attenuated) vaccine could be safely postponed until after the study were eligible to enroll in the study
  • Patients who had their vaccination preponed (given prior to the study) could enroll in the trial only after a gap of 4 weeks following administration of the vaccine

In the adult dupilumab clinical studies, treatment with a live vaccine within 12 weeks before the baseline visit was prohibited. Subjects who received a live vaccine during the clinical study were immediately discontinued from the study treatment. Subjects who completed the study treatment were advised not to administer live vaccines for approximately 3 months after stopping dupilumab.2,10

Nonlive vaccines

Limited data are available regarding coadministration of DUPIXENT with non-live vaccines.

Immune responses to vaccination were assessed in a study in which adult subjects with atopic dermatitis were treated once weekly for 16 weeks with 300 mg of dupilumab (twice the recommended dosing frequency). After 12 weeks of DUPIXENT administration, subjects were vaccinated with a Tdap vaccine (Adacel®) and a meningococcal polysaccharide vaccine (Menomune®). Antibody responses to tetanus toxoid and serogroup C meningococcal polysaccharide were assessed 4 weeks later. Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab-treated and placebo-treated subjects. Immune responses to the other active components of the Adacel and Menomune vaccines were not assessed.1,10